Considerable efforts are being made in the search for suitable candidates for an effective serogroup B meningococcal vaccine, but with limited success. We have identified a novel, high molecular weight antigen of approximately 200 kDa. The antigen was expressed during invasive disease as 100% of convalescent case sera contained antibody compared with approximately 50% of carriers. Many clinical isolates did not appear to express the 200 kDa antigen, but corresponding sera contained antibody, indicating in vivo expression. Antibody to this antigen cross-reacted with meningococci of diverse phenotypes. Further investigation of this antigen is required to determine its potential as a future vaccine component.
|Number of pages||6|
|Journal||Serodiagnosis and Immunotherapy in Infectious Disease|
|Publication status||Published - Jan 1997|
Bibliographical noteFunding Information:
This study was funded by the Medical Research Council. UK. grant number SPG 911663 1.
- High molecular weight protein